Ascendis Pharma ADR ASND

$227.87 +0.56 (0.25%)

Valuation

Market cap
14,178,914,000
Revenue TTM
$814,760,000
Net income TTM
$-258,000,000
PE ratio
126.57
Forward PE
64.26
Profit margin
-31.67%
Debt to equity
0.31

Trading

Volume
641,400
Avg volume
678,532
Day's range
$225.20 – $229.02
Shares out
62,377,000
Stochastic %K
37%
Beta
0.38
Analysts
Strong Sell
Price target
$314.75

Price

Company profile

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipe...

Show more

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

Industry
Biotechnology
Sector
Healthcare
Phone
45 70 22 22 44
Website
https://ascendispharma.com
Address
Tuborg Boulevard 12, Hellerup, Denmark

Latest news

Stocktwits

Quantumup Oct 2, 12:50 PM
Guggenheim⬆️ $MBX's PT to $150 & reit'd Buy. ~Believes MBX 4291, should the Part C data show a once-monthly profile that is competitive with tirz—canvuparatide could make MBX a $8B+ Co.—rest of the obesity portfolio remain pot'l upside. $LLY VKTX NVO GPCR KLRA $ASND RHHBY Here's what Guggenheim said in its note to investors: https://x.com/Quantumup1/status/2106003575075676364?s=20
0 replies
NVDAMillionaire Sep 22, 8:34 AM
$ASND Brilliant piece that captures ASND's situation perfectly. So if you want to update your understanding of ASND or get to know ASND better, this is essential reading. https://everyticker.com/quote/ASND/analysis/transcon-platform-delivers-third-blockbuster-why-ascendis-pharma-s-rare-disease-trifecta-changes-the-risk-reward-equation-nasdaq-asnd
0 replies
CaptainAmrica Sep 18, 2:02 PM
$ASND $GMAB . Sold for a little gain.
0 replies
Hognose Sep 17, 10:10 PM
$ABVX $ASND $USAR good dip buy zones.
0 replies
Hognose Sep 17, 2:55 AM
$AVAV $ABVX $ASND $APLD $AMZN my bullish A's.
0 replies
notreload_ai Sep 15, 5:12 PM
$ASND will develop TransCon obesity and cardiometabolic programs itself after ending its $NVO collaboration and starting a $400M buyback. https://notreload.xyz/xy/ascendis-reclaims-obesity-rights-authorizes-400m-buyback/
0 replies
Arcides Sep 15, 4:20 PM
$ASND
0 replies
MUNEMAKER Sep 15, 1:53 PM
$ASND @Pika_Capital Overreaction to the news today?
1 replies